Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine

Journal of Dermatological Science

Volumn 75, Issue 1, 2014, Pages 49-54

  Piwnica, David ^a   Rosignoli, Carine ^a   de Ménonville, Séverine Thibaut ^a   Alvarez, Thierry ^a   Schuppli Nollet, Marlene ^a   Roye, Olivier ^a   Jomard, André ^a   Aubert, JérÔme ^a  

^a Research Galderma   (France)

Author keywords

Brimonidine; Inflammation; Mirvaso; Pharmacology; Rosacea; Vascular

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; BRIMONIDINE; OXYMETAZOLINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIINFLAMMATORY AGENT; QUINOXALINE DERIVATIVE; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; EAR EDEMA; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; MYOGRAPHY; NONHUMAN; OTITIS; PRIORITY JOURNAL; SKIN BIOPSY; VASOCONSTRICTION; ANIMAL; BAGG ALBINO MOUSE; BIOPSY; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; METABOLISM; SKIN; TISSUE CULTURE TECHNIQUE; VASCULARIZATION; VASODILATATION;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOPSY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATION; MICE, INBRED BALB C; QUINOXALINES; RECEPTORS, ADRENERGIC, ALPHA-2; SKIN; TISSUE CULTURE TECHNIQUES; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 84901672379     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2014.04.002     Document Type: Article

References (30)

1. Crawford G.H., Pelle M.T., James W.D., Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004, 51:327-341.
2. Wilkin J., Dahl M., Detmar M., Drake L., Feinstein A., Odom R., et al. Standard classification of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2002, 46:584-587.
3. Wilkin J., Dahl M., Detmar M., Drake L., Liang M.H., Odom R., et al. Standard grading system for rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2004, 50:907-912.
4. Odom R., Dahl M., Dover J., Draelos Z., Drake L., Macsai M., et al. Standard management options for rosacea, Part I: overview and broad spectrum of care. Cutis 2009, 84:43-47.
5. Gupta A.K., Chaudhry M.M. Rosacea and its management: an overview. J Eur Acad Dermatol Venereol 2005, 19:273-285.
6. Del Rosso J.Q. Advances in understanding and managing rosacea: part 2. The central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea. J Clin Aesthet Dermatol 2012, 5(3):26-36.
7. Steinhoff M., Buddenkotte J., Aubert J., Sulk M., Novak P., Scwab V.D., et al. Clinical, cellular and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011, 15:2-11.
8. Wilkin J.K., Rosacea: Pathophysiology and treatment. Arch Dermatol 1994, 130:359-362.
9. Del Rosso J.Q. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clin Aesthet Dermatol 2012, 5:16-25.
10. Fowler J., Jackson J.M., Moore A., Jarratt M., Jones T., Meadows K., et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol 2013, 12(6):650-656.
11. Del Rosso J.Q., Gallo R.L., Tanghetti E., Webster G., Thiboutot An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis 2013, 91(3S):1-8.
12. Rosina P., Zamperetti M.R., Giovannini A., Chieregato C., Girolomoni G. Videocapillaroscopic alterations in erythematotelangiectatic rosacea. J Am Acad Dermatol 2006, 54:100-104.
13. Schwab V.D., Sulk M., Seeliger S., Nowak P., Aubert J., Mess C., et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011, 15:53-62.
14. Yamasaki K., Di Nardo A., Bardan A., Murakami M., Ohtake T., Coda A., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007, 13(August):975-980.
15. Helfrich Y.R., Varani J., Fisher G.J., Chubb H., Hammerberg C., Bruce A., et al. Mast cell and neuropeptide expression are increased in erythematotelangiectatic rosacea in comparison to telangiectatic photoaging. Poster presented at: Society for Investigative Dermatology Annual Meeting 2012, P093.
16. Tan S.G., Cunliffe W.J. Rosacea and migraine. Br Med J 1976, 3(January):21.
17. Spoendlin J., Voegel J.J., Jick S.S., Meier C.R. Migraine, triptans, and the risk of developing rosacea: a population-based study within the United Kingdom. J Am Acad Dermatol 2013, 69(September (3)):399-406.
18. Shanler S.D., Ondo A.L. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol 2007, 143(11):1369-1371.
19. Bikowski J. Rosacea therapy: current approaches and future directions. Pract Dermatol 2012, (July):31-32.
20. Fowler J., Jarratt M., Moore A., Meadows K., Pollack A., Steinhoff M., et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 2012, 166:633-641.
21. Rahman M.Q., Ramaesh K., Montgomery D.N.I. Brimonidine for glaucoma. Expert Opin Drug Saf 2010, 9:483-491.
22. Serle J.B. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol 1996, 41(Suppl 1):S39-S47.
23. Katz L.J. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine study group. Am J Ophthalmol 1999, 127:20-26.
24. Cantor L.B. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother 2000, 1(4):815-834.
25. Mirvaso® Prescribing Information.
26. Moore A., Kempers S., Murakawa G., et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-labeled study. J Drugs Dermatol 2014, 13(1):56-61.
27. Huang X.P., Setola V., Yadav P.N., Allen J.A., Rogan S.C., Hanson B.J., et al. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment. Mol Pharmacol 2009, 76:710-722.
28. Hsia E., Tian M., Santori E., Mistry D., Gil D. The alpha adrenergic receptor agonist oxymetazoline inhibits temperature-induced vasodilation and LL-37 induced skin inflammation. J Investig Dermatol 2012, 132:S1-S18.
29. Cribier B. Rosacea under the microscope: characteristic histological findings. J Eur Acad Dermatol Venereol 2013, 27(November (11)):1336-1343.
30. Tian M., Hsia E., Andrews-Jones L., Manley K., Azartash K., Cheevers C., et al. The alpha adrenergic receptor agonist oxymetazoline decreases erythema and inflammation in a UVB-induced sunburn model. J Investig Dermatol 2013, 133:S209-S221.